

A Practical Approach to Pharmaceutical Policy

Andreas Seiter



THE WORLD BANK
Washington, D.C.

Contents

<i>Foreword</i>		<i>xi</i>
<i>Preface</i>		<i>xiii</i>
<i>Acknowledgments</i>		<i>xv</i>
<i>About the Author</i>		<i>xvii</i>
<i>Abbreviations</i>		<i>xix</i>
Chapter 1	Pharmaceutical Policy Goals	1
	Pharmaceutical Policy Framework	3
	Parameters for Monitoring the Effect and Progress of Pharmaceutical Reforms	6
	References	10
Chapter 2	Introducing the Stakeholders	11
	Multinational Research-Based Companies	13
	Multinational Generics Companies	18
	National Generics Companies	21
	Brokers	22
	Procurement Agents	23
	Importers and Agents	24
	Wholesalers	25
	Central Medical Stores	26

	Retail Pharmacists and Drug Sellers	27
	Prescribers	28
	Consumers	29
	Public Policy Makers: Legislative and Executive	30
	Regulatory and Executive Agencies	31
	Expert Commissions and Advisers	32
	Civil Society Organizations	32
	International Agencies and Donors	33
	Public Purchasers	35
	Payers	35
	Pharmaceutical Benefit Managers	36
	Consultants	36
	Notes	37
	References	38
Chapter 3	Patterns of Dysfunction	39
	Inadequate Regulation of Core Pharmaceutical Sector Functions	41
	Lack or Misuse of Funds	44
	Ineffective or Inefficient Procurement	45
	Dysfunctional Supply Chains	48
	Corruption, Abuse of Public Funds, and Unethical Business Practices	51
	Inadequate Incentives for Providers and Policy Makers	53
	Medicine Prices Perceived as Too High	59
	Conflicts between Innovation and Cost Containment	66
	Conflicts between Industrial Policy and Public Health Objectives	71
	Irrational or Inappropriate Use of Drugs	73
	A Tool to Assess the Sector and Diagnose Dysfunctions	75
	Notes	77
	References	78
Chapter 4	Key Elements of a Successful Pharmaceutical Policy	81
	Ensuring Access to Safe and Effective Drugs through Well-Designed Supply Chains	82

	Using Purchasing Power to Get Value for Money	93
	Managing the Decision Process on Formulary Inclusion	97
	Creating Adequate Information Systems	104
	Ensuring Rational and Cost-Effective Use of Medicines	107
	Securing Adequate Financing and Payment Mechanism for Pharmaceuticals	110
	Reconciling Health Policy and Industrial Policy in the Pharmaceutical Sector	113
	Ensuring Good Governance of the Sector	117
	Notes	120
	References	121
Chapter 5	Policy Packages to Achieve Strategic Long-Term Goals	123
	Essential Medicines Policy	124
	Generic Drugs Policy	126
	Innovation-Friendly Drugs Policy	127
	Combining Several Policy Models within One Country	128
	Notes	129
	Reference	129
Chapter 6	Factors Influencing Policy Implementation	131
	Stakeholder Assessment and Involvement	132
	Strategies to Neutralize Political Opposition	135
	Note	137
	Reference	137
Chapter 7	Pharmaceutical Policy Illustrated in Country Examples	139
	Ghana: National Health Insurance as a “Game Changer”	139
	Lithuania: Dealing with the Effects of the Financial Crisis	143
	China: Improving Social Protection for the Rural Poor	145
	Russian Federation: Affordability and Access to Essential Drugs	146

	Liberia: Building Up after Conflict	147
	Notes	149
	References	149
Chapter 8	Pharmaceutical Policy Outlook	151
	Regulatory Framework	151
	Drug Prices	153
	Financing and Management of Drug Benefits	154
	Effect on Markets and Industry	155
	General Trend: Convergence toward Models That Work	158
	References	159
Appendix A	A Tool to Assess the Pharmaceutical Sector in a Given Country	161
Appendix B	Customized Version of the Assessment Tool (Appendix A) for Use in an Assessment of the Pharmaceutical Sector in Turkey	167
	Part 1: Quantitative Data	169
	Part 2: Descriptive Section	171
Appendix C	Assessment Tool for Government Procurement Agencies in the Health Sector in India	175
Index		207
Boxes		
1.1	Example of Target Setting in a Project Aimed at Improving Access to Medicines in a Low-Income Country	8
2.1	A Tragedy in Panama, Caused by a Toxic Ingredient in Cough Syrup	21
3.1	Major Cost Drivers for Ensuring Drug Availability in Health Centers in Lesotho	50
3.2	Fraudulent Abuse of Health Insurance Funds in Germany	53
3.3	Example of Price Regulation in Practice	62
3.4	NICE: Example of an Institution Set Up to Manage the Conflict between Innovation and Cost Containment in Health Care	69
3.5	Access to Medicines and the TRIPs Agreement in Brazil	70